Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Trading 10-16 11:39:30 EDT

1.88

-0.05

-2.60%

High1.95	Low1.87	Vol530.66K
Open1.94	D1 Closing1.93	Amplitude4.16%
Mkt Cap225.00M	Tradable Cap196.75M	Total Shares120.00M
T/O1.01M	T/O Rate0.51%	Tradable Shares104.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":1.875,"timestamp":1792165168614,"preClose":1.925,"halted":0,"volume":530656,"delay":0,"changeRate":-0.025974025974025997,"floatShares":104935918,"shares":120000000,"eps":-1.052849,"marketStatus":"Trading","change":-0.05,"latestTime":"10-16 11:39:30 EDT","open":1.94,"high":1.95,"low":1.87,"amount":1012864.168512,"amplitude":0.041558,"askPrice":1.88,"askSize":4900,"bidPrice":1.87,"bidSize":2712,"shortable":3,"etf":0,"ttmEps":-1.052849,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1792180800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":1.925,"preHourTrading":{"tag":"盘前","latestPrice":1.96,"preClose":1.925,"latestTime":"08:26 EDT","volume":98,"amount":183.5303036,"timestamp":1792153599219,"change":0.035,"changeRate":0.018182,"amplitude":0.051948},"postHourTrading":{"tag":"盘后","latestPrice":1.9032,"preClose":1.925,"latestTime":"19:30 EDT","volume":9679,"amount":18632.9732,"timestamp":1792107004416,"change":-0.0218,"changeRate":-0.011325,"amplitude":0.011325},"volumeRatio":1.537854,"impliedVol":1.3684,"impliedVolPercentile":0.7251},"requestUrl":"/m/hq/s/FATE/tweets","defaultTab":"tweets","newsList":[{"id":"2674748468","title":"Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of Car T-Cell Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2674748468","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674748468?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:00","pubTimestamp":1791802801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUA5YMGR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674004871","title":"Press Release: Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-Cell Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2674004871","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674004871?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:00","pubTimestamp":1791802800,"startTime":"0","endTime":"0","summary":"Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trialProven record in advancing breakthrough autoimmune therapies and establis","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4022","BK4139","BK4232","R","BK4007","FATE","LENZ","DBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672845719","title":"Fate Therapeutics Reports New Employee Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672845719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672845719?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:00","pubTimestamp":1790938800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nTUA8TDPCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672195947","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672195947","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672195947?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:00","pubTimestamp":1790938800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3373739/24675/en/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","LCLG","BK4139","LENZ","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672713141","title":"Fate Therapeutics (FATE) Securities Case Faces Another Motion to Dismiss After 2025 Dismissal Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2672713141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672713141?lang=en_us&edition=fundamental","pubTime":"2026-10-02 17:11","pubTimestamp":1790932312,"startTime":"0","endTime":"0","summary":"In a September 22, 2025 ruling, a federal judge dismissed the then-operative securities fraud complaint against Fate Therapeutics, Inc. ($FATE), ho...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/fate-therapeutics-fate-securities-case-faces-another-motion-to-dismiss-after-2025-dismissal-order?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/fate-therapeutics-fate-securities-case-faces-another-motion-to-dismiss-after-2025-dismissal-order?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672751366","title":"Fate Therapeutics to Join Jefferies, Piper Sandler Investor Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2672751366","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672751366?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:05","pubTimestamp":1790852716,"startTime":"0","endTime":"0","summary":"Fate Therapeutics to join Jefferies, Piper Sandler investor healthcare conferencesFate Therapeutics management will attend the 2026 Jefferies Global Healthcare Conference in London on Nov. 16-19.Parti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL6bMqK5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BQXX3D17.EUR","LU2210149790.SGD","LU0053671581.USD","IE00B64PRP62.GBP","PIPR","SG9999014005.SGD","SG9999014039.USD","IE00BKPKM429.USD","BK4112","IE00BN0W2V16.EUR","LU0314104364.USD","LU2095319765.USD","BK4585","BK4127","SG9999014013.SGD","IE00BN0W2W23.USD","FATE","IE00BQXX3C00.GBP","NDAQ","SG9999014021.USD","BCDF","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672475181","title":"Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2672475181","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672475181?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:00","pubTimestamp":1790852400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372716/24675/en/fate-therapeutics-to-participate-in-upcoming-fourth-quarter-2026-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4139","FATE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670440027","title":"Sector Update: Healthcare Stocks Edge Higher Premarket Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2670440027","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670440027?lang=en_us&edition=fundamental","pubTime":"2026-09-25 21:19","pubTimestamp":1790342373,"startTime":"0","endTime":"0","summary":"Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) advancing by 0.5%.STAAR Surgical (","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2168564495.EUR","LU2456880835.USD","AGNG","LU2552382058.USD","GB00BDT5M118.USD","IE0001KFT4U8.USD","LU2264538146.SGD","LU1868837136.USD","SGXZ99366536.SGD","LU0122379950.USD","LU2361045086.USD","LU2028103732.USD","SG9999001176.USD","LU1868836757.USD","LU0354030511.USD","LU0096364046.USD","LU1145028129.USD","LU2237443895.HKD","MEDX","LU2756315318.SGD","CURE","LU1623119135.USD","OZEM","LU0820561909.HKD","LU1551013425.SGD","LU0820561818.USD","LU2237443382.USD","MHIP","LU2089283258.USD","CANC","IE00BFSS7M15.SGD","LU1291159041.SGD","LU0345770993.USD","LU2462591350.SGD","LU1989771016.USD","LU2746668461.USD","ELIL","LU2063271972.USD","IE00BJJMRZ35.SGD","LU2357305700.SGD","LU2756315664.SGD","LU2750360997.AUD","FHLC","LU1061106388.HKD","LU0006306889.USD","LU1691799644.USD","LU0320765992.SGD","IBB","IE0005OL40V9.USD","LU0174119429.USD","SGXZ31699556.SGD","THNR","LU0385154629.USD","SG9999018857.SGD","LU2237438978.USD","PPH","IE00B4R5TH58.HKD","SG9999001176.SGD","LU0708995401.HKD","FATE","LU0198837287.USD","IE00BK4W5M84.HKD","LU2750360641.GBP","LU0234572021.USD","LU2087625088.SGD","LU0079474960.USD","LU1988902786.USD","LU0353189763.USD","IE00BK4W5L77.USD","LU2471134523.USD","WDNA","LU0158827948.USD","IE00BWXC8680.SGD","LU1093756325.SGD","LLY","LU0683600562.USD","LU0417517546.SGD","LU0210536198.USD","LU2168564065.EUR","IE0004445239.USD","VHT","IE00BFSS8Q28.SGD","SGXZ51526630.SGD","ILDR","LU2112291526.USD","LU2211815571.USD","LU0061475181.USD","BK4533","LU2089284900.SGD","LU0203202063.USD","BK4588","LU1720051017.SGD","FTXH","IE00B1BXHZ80.USD","LU0354030438.USD","LU0097036916.USD","LU1057294990.SGD","LLYZ","LU0203201768.USD","LU0225283273.USD","LU0823416689.USD","LU0823434583.USD","LU0823434740.USD","LU0058720904.USD","LU2111349929.HKD","LU2236285917.USD","LU2552382132.HKD","SG9999015952.SGD","LU2237443465.HKD","LU0158827781.USD","SG9999015978.USD","LU0882574139.USD","STAA","IE00B4JS1V06.HKD","LU1064131342.USD","HRTS","IE0009355771.USD","TRUH","BK4139","IE00B1XK9C88.USD","LU2471134952.CNY","IE00BJJMRY28.SGD","IE00BFTCPJ56.SGD","LU2023250504.SGD","NKTR","LU1280957306.USD","LU0289739699.SGD","LU2461242641.AUD","LU0323591593.USD","BK4516","LU2108987350.USD","BK4581","SGXZ81514606.USD","LU2896262040.SGD","XLV","LU0640476718.USD","LU1974910355.USD","LLII","LU2023250330.USD","LU1979441026.SGD","LU1093756168.USD","LU0133085943.USD","LU0471298694.HKD","LU0471298777.SGD","LU1868837300.USD","LU0114720955.EUR","LU1917777945.USD","LU2213496289.HKD","LU0689472784.USD","LU1023059063.AUD","LU2237443549.SGD","LU2491050154.USD","LU0256863811.USD","LU2265009873.SGD","LU2106854487.HKD","MEDI","SG9999014906.USD","BK4007","LU0882574055.USD","LU0432979614.USD","LU0889565916.HKD","IE00BJT1NW94.SGD","LU0266013472.USD","TMED","LU2089984988.USD","LU0256863902.USD","LU1548497426.USD","LU1551013342.USD","SG9999013999.USD","LU2237443622.USD","IE00BKDWB100.SGD","IE00BJLML261.HKD","LU2168563687.JPY","SG9999018865.SGD","LU2271345857.HKD","LU2491049909.HKD","IE00BJJMRX11.SGD","IE0002141913.USD","LU1720051108.HKD","LU1868836591.USD","XBI","BK4599","LU1323610961.USD","LU1804176565.USD","LU0964807845.USD","LU0094547139.USD","LU1814569148.SGD","LU1868836914.USD","LU2324357040.USD","LU2491050071.SGD","SG9999017495.SGD","LU0787776722.HKD","LU2360106947.USD","LU0109394709.USD","LU0466842654.USD","SG9999014898.SGD","JDOC","LU0320765059.SGD","LU0345770308.USD","LU0316494557.USD","LU2237443978.SGD","LU2468319806.SGD","LU0238689110.USD","LU2602419157.SGD","LU0353189680.USD","LU1267930730.SGD","LU2361044949.HKD","LU2168564149.EUR","IE0004445015.USD","LLYX","BK4548","GDOC","IE00BKPKM429.USD","IHE","LU0820562030.AUD","LU1232071149.USD","LU0786609619.USD","LU2471134879.HKD","BK4198","IE00BN29S564.USD","SGXZ57979304.SGD","LU1127390331.HKD","LU2168564222.USD","LU2471134796.USD","LABU","LU2361044865.SGD","LU1366192091.USD","ELIS","IE00B7KXQ091.USD","IXJ","LU1629891620.HKD","LU1035775433.USD","IE00B775H168.HKD","IYH","LU0109391861.USD","LU2417539215.USD","LU2552382215.SGD","LU1069344957.HKD","LU0943347566.SGD","PJP","LU1983299246.USD","LU2462157665.USD","LU2746668974.SGD","SG9999015945.SGD","SG9999014880.SGD","LU2023251221.USD","BK4534","LU0672654240.SGD","IE00B2B36J28.USD","RXL","SG9999015986.USD","SG9999014914.USD","LU0456855351.SGD","LU1712237335.SGD","BK4585","LU0106261372.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670144287","title":"Fate Therapeutics - Receives $15 Mln Award for Phase 2 FT819 Trial in Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2670144287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670144287?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:01","pubTimestamp":1790334093,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nFWN45G1D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670381442","title":"Fate Therapeutics Wins $15 Million CIRM Grant for FT819 Lupus Nephritis Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2670381442","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670381442?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:01","pubTimestamp":1790334067,"startTime":"0","endTime":"0","summary":"Fate Therapeutics wins $15 million CIRM grant for FT819 lupus nephritis Phase 2 trialFate Therapeutics won a USD 15 million CLIN2 grant from the California Institute for Regenerative Medicine to advan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nNDL5QD4M0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BN0W2W23.USD","NDAQ","FATE","LU2210150020.SGD","SG9999014021.USD","BK4112","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","LU2095319765.USD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","BCDF","BK4139","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014013.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607273","title":"Fate Therapeutics Launches Phase 1/2 Complete Trial of FT839 Dual-CAR T Therapy in Rheumatoid Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607273","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607273?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:01","pubTimestamp":1789556500,"startTime":"0","endTime":"0","summary":"Fate Therapeutics launches Phase 1/2 COMPLETE trial of FT839 dual-CAR T therapy in rheumatoid arthritisFate Therapeutics secured four ACR Convergence 2026 poster slots for its off-the-shelf CAR T-cell","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDLbxzZcj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","BK4112","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014021.USD","IE00BQXX3D17.EUR","LU2210150020.SGD","SG9999014005.SGD","FATE","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014013.SGD","LU0314104364.USD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4588","NDAQ","BK4585","IE00BKPKM429.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538541","title":"Fate Therapeutics announces clinical data from FT819 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538541?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:45","pubTimestamp":1788954325,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (FATE) announced clinical data from its off-the-shelf anti-CD19 CAR T-cell product candidate FT819, and pre-clinical data from it...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-announces-clinical-data-from-ft819-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-announces-clinical-data-from-ft819-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CAR","BK4022","FATE","BK4230","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666631587","title":"Fate Therapeutics Presents Phase 1 Data for Off-the-Shelf CAR-T FT819 in Systemic Lupus Erythematosus at CCR-West 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2666631587","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666631587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:06","pubTimestamp":1788951970,"startTime":"0","endTime":"0","summary":"Fate Therapeutics presents Phase 1 data for off-the-shelf CAR-T FT819 in systemic lupus erythematosus at CCR-West 2026Fate Therapeutics set an encore clinical data presentation on FT819 at the CCR – W","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL9RfVnK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","LU2095319765.USD","NDAQ","LU0314104364.USD","BK4585","FATE","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BQXX3F31.USD","BCDF","IE00BQXX3D17.EUR","SG9999014021.USD","BK4588","SG9999014039.USD","BK4139","LU2210149790.SGD","IE00BKPKM429.USD","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666858794","title":"Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666858794","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666858794?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358477/24675/en/fate-therapeutics-announces-encore-clinical-data-presentation-of-ft819-off-the-shelf-car-t-cell-product-candidate-at-the-ccr-west-2026-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","FATE","BK4077","IDNA","CCR","MEDX","NVIB","HYLG","BK4139","GDOC","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664876078","title":"Fate Therapeutics Joins Cantor Global Healthcare Conference Fireside Chat on FT819 Autoimmune CAR-T Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2664876078","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664876078?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:03","pubTimestamp":1788433419,"startTime":"0","endTime":"0","summary":"Fate Therapeutics joins Cantor Global Healthcare Conference fireside chat on FT819 autoimmune CAR-T programFate Therapeutics management will join a fireside chat at the 2026 Annual Cantor Global Healt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL7WdDvt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B64PRP62.GBP","IE00BKPKM429.USD","BCDF","BK4585","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","SG9999014013.SGD","IE00BQXX3F31.USD","BK4112","IE00BQXX3C00.GBP","LU2095319765.USD","BK4588","IE00B3QW5Z07.USD","FATE","SG9999014039.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014021.USD","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664584356","title":"Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664584356","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664584356?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:31","pubTimestamp":1788366686,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc ($FATE) announced an update on their ongoing clinical study. Fate Therapeutics Inc. is advancing a new early stage trial call...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-expands-into-autoimmune-disease-with-new-ft839-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-expands-into-autoimmune-disease-with-new-ft839-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659177808","title":"Fate Therapeutics intiates first patient in RECLAIM-LN trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659177808","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659177808?lang=en_us&edition=fundamental","pubTime":"2026-08-16 21:40","pubTimestamp":1786887614,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (FATE) highlighted the initiation of and treatment of the first patient in RECLAIM-LN, its Phase 2 potentially registrational cli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-intiates-first-patient-in-reclaim-ln-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-intiates-first-patient-in-reclaim-ln-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144490","title":"Fate Therapeutics Price Target Maintained with a $7.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144490","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144490?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:20","pubTimestamp":1786713600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FATE/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659314328","title":"Fate Therapeutics - Patients to Receive Single 900 Mln-Cell Dose of Ft819; Primary Endpoint at Week 26","url":"https://stock-news.laohu8.com/highlight/detail?id=2659314328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659314328?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA8L2JHJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659143408","title":"Fate Therapeutics Initiates Potentially Registrational Reclaim-Ln Clinical Trial of FT819 for the Treatment of Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2659143408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659143408?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA8L2JHJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0962},{"period":"1month","weight":-0.1809},{"period":"3month","weight":-0.3076},{"period":"6month","weight":0.3849},{"period":"1year","weight":0.2582},{"period":"ytd","weight":0.9591}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.019},{"period":"3month","weight":0.0383},{"period":"6month","weight":0.0868},{"period":"1year","weight":0.1603},{"period":"ytd","weight":0.1318}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.049458},{"month":2,"riseRate":0.615385,"avgChangeRate":0.078089},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.020579},{"month":4,"riseRate":0.615385,"avgChangeRate":0.004138},{"month":5,"riseRate":0.461538,"avgChangeRate":0.079338},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.000833},{"month":7,"riseRate":0.384615,"avgChangeRate":0.039214},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.024594},{"month":9,"riseRate":0.384615,"avgChangeRate":0.000021},{"month":10,"riseRate":0.230769,"avgChangeRate":-0.099},{"month":11,"riseRate":0.538462,"avgChangeRate":0.090829},{"month":12,"riseRate":0.538462,"avgChangeRate":0.045045}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}